9lg0

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (05:55, 1 October 2025) (edit) (undo)
 
Line 1: Line 1:
-
'''Unreleased structure'''
 
-
The entry 9lg0 is ON HOLD until 2027-01-09
+
==Crystal Structure of Human Peroxiredoxin I in Complex with SAB==
 +
<StructureSection load='9lg0' size='340' side='right'caption='[[9lg0]], [[Resolution|resolution]] 1.81&Aring;' scene=''>
 +
== Structural highlights ==
 +
<table><tr><td colspan='2'>[[9lg0]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=9LG0 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=9LG0 FirstGlance]. <br>
 +
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.81&#8491;</td></tr>
 +
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=A1LXC:(2~{R})-3-[3,4-bis(oxidanyl)phenyl]-2-[(~{E})-3-[(2~{S},3~{S})-2-[3,4-bis(oxidanyl)phenyl]-3-[(2~{R})-3-[3,4-bis(oxidanyl)phenyl]-1-oxidanyl-1-oxidanylidene-propan-2-yl]oxycarbonyl-7-oxidanyl-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyl]oxy-propanoic+acid'>A1LXC</scene></td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=9lg0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=9lg0 OCA], [https://pdbe.org/9lg0 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=9lg0 RCSB], [https://www.ebi.ac.uk/pdbsum/9lg0 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=9lg0 ProSAT]</span></td></tr>
 +
</table>
 +
== Function ==
 +
[https://www.uniprot.org/uniprot/PRDX1_HUMAN PRDX1_HUMAN] Involved in redox regulation of the cell. Reduces peroxides with reducing equivalents provided through the thioredoxin system but not from glutaredoxin. May play an important role in eliminating peroxides generated during metabolism. Might participate in the signaling cascades of growth factors and tumor necrosis factor-alpha by regulating the intracellular concentrations of H(2)O(2). Reduces an intramolecular disulfide bond in GDPD5 that gates the ability to GDPD5 to drive postmitotic motor neuron differentiation (By similarity).
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent inflammation and joint damage, accompanied by the accumulation of plasma cells, which contributes to its pathogenesis. Understanding the genetic alterations occurring during plasma cell differentiation in RA can deepen our comprehension of its pathogenesis and guide the development of targeted therapeutic interventions. Here, our study elucidates the intricate molecular mechanisms underlying plasma cell differentiation by demonstrating that PRDX1 interacts with DOK3 and modulates its degradation by the autophagy-lysosome pathway. This interaction results in the inhibition of plasma cell differentiation, thereby alleviating the progression of collagen-induced arthritis. Additionally, our investigation identifies Salvianolic acid B (SAB) as a potent small molecular glue-like compound that enhances the interaction between PRDX1 and DOK3, consequently impeding the progression of collagen-induced arthritis by inhibiting plasma cell differentiation. Collectively, these findings underscore the therapeutic potential of developing chemical stabilizers for the PRDX1-DOK3 complex in suppressing plasma cell differentiation for RA treatment and establish a theoretical basis for targeting PRDX1-protein interactions as specific therapeutic targets in various diseases.
-
Authors: Xu, H., Luo, C.
+
Augmentation of PRDX1-DOK3 interaction alleviates rheumatoid arthritis progression by suppressing plasma cell differentiation.,Dang W, Wang X, Li H, Xu Y, Li X, Huang S, Tao H, Li X, Yang Y, Xuan L, Xiao W, Guo D, Zhang H, Wu Q, Zheng J, Shen X, Chen K, Xu H, Zhang Y, Luo C Acta Pharm Sin B. 2025 Aug;15(8):3997-4013. doi: 10.1016/j.apsb.2025.06.006. Epub , 2025 Jun 9. PMID:40893682<ref>PMID:40893682</ref>
-
Description: Crystal Structure of Human Peroxiredoxin I in Complex with SAB
+
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-
[[Category: Unreleased Structures]]
+
</div>
-
[[Category: Luo, C]]
+
<div class="pdbe-citations 9lg0" style="background-color:#fffaf0;"></div>
-
[[Category: Xu, H]]
+
== References ==
 +
<references/>
 +
__TOC__
 +
</StructureSection>
 +
[[Category: Homo sapiens]]
 +
[[Category: Large Structures]]
 +
[[Category: Luo C]]
 +
[[Category: Xu H]]

Current revision

Crystal Structure of Human Peroxiredoxin I in Complex with SAB

PDB ID 9lg0

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools